新生血管性年龄相关性黄斑变性药物治疗的进步和展望

年龄相关性黄斑变性( AMD)已成为老龄人口视力丧失的主要原因,随着老龄化的发展,AMD已经成为严重的公共卫生问题.其中,湿性AMD以脉络膜新生血管(CNV)为主要特征,病情进展迅速,对视力危害严重,一直以来,临床上却没有切实有效的治疗方法.近20年,随着对疾病治疗的探索,针对CNV的治疗成为关注的焦点,从实验室到临床,针对新生血管生成的靶向治疗研究给湿性AMD的药物治疗带来了新的希望,有望大大减少湿性AMD的致盲率.总结临床前沿科研结果,介绍湿性AMD的最新治疗进展.

Current progression and prospect in the targeting therapy of age-related macular degeneration

Age-related macular degeneration (AMD) has become a leading cause of irreversible visual loss in senior population and a serious issue of public health as the aging of society worldwide,especially wet AMD.Wet AMD is characterized by choroidal neovascularization (CNV) with a rapidly developing process and severe impairment of visual acuity.The effective therapy that can destroy choroidal neovascularization and improve visual acuity for very long time is lack.In the recent 20 years,more attentions focuse on the treatment of choroidal neovascularization.From bench to bedside,the research on targeted treatment of angiogenesis brings the bloom of wet AMD medical therapy.This paper will summarize the update information of wet AMD.